眾生藥業(002317.SZ)“一種新的生物醫用聚醚/聚酯嵌段共聚物的製備方法”獲專利證書
格隆匯10月31日丨眾生藥業(002317.SZ)公佈,近日,公司“一種新的生物醫用聚醚/聚酯嵌段共聚物的製備方法”收到中華人民共和國國家知識產權局頒發的發明專利證書。
該專利是公司研發的用於治療包括乳腺癌、非小細胞肺癌、卵巢癌等癌症的改良型新藥注射用紫杉醇聚合物膠束和注射用多西他賽聚合物膠束的關鍵聚合物輔料專利,屬於項目的重要專利。該專利所涉注射用紫杉醇聚合物膠束和注射用多西他賽聚合物膠束為採用聚合物輔料mPEG-PDLLA對活性成分進行物理包裹,製備成具有核-殼結構的聚合物膠束,與現有傳統紫杉醇/多西他賽制劑相比具有組織被動靶向性及增效減毒作用,同時還可避免現有傳統制劑的過敏反應等毒副作用,具有更好的臨牀使用安全性及臨牀應用前景,目前項目已經獲得藥物臨牀試驗批件,相關臨牀試驗工作正按計劃積極推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.